石药集团巨石生物ADC新产品商业化生产线建设项目拟在石家庄高新区仓盛路519号石药集团巨石生物制药有限公司厂区内实施，在巨石生物建设四条生产线及配套的集中称量、尾气吸收系统、生物废水灭活系统等，购置反应器、碟片离心机、层析系统、灌装线等工艺设备。项目建成后将增加巨石生物ADC产品的原液和制剂产能。项目总投资估算为不超过4亿元(含)，项目建设周期预计为21个月。CSPC Pharma, a subsidiary controlled by CSPC Innovation Pharmaceutical (300765.SZ), announced that it plans to invest in the construction of the "CSPC Pharma JS Bio Large Biopharmaceutical Production Line Construction" and "CSPC Pharma JS Bio ADC New Product Commercial Production Line Construction" projects. The monoclonal antibody production line project is planned to be implemented in the factory area of CSPC Pharma JS Bio Pharmaceutical Co., Ltd. at No. 519 Cangsheng Road, High-tech Zone, Shijiazhuang. Three production lines and supporting material automatic conveying systems, biological wastewater inactivation systems, and new facilities such as automatic detection function islands will be built in JS Bio. Process equipment such as disposable bioreactors, disk centrifuges, chromatography systems, lyophilizers, and filling lines will also be purchased. After the project is completed, the production capacity of the original liquid and preparation of JS Bio monoclonal antibody products will be increased. The total estimated investment of the project is not more than RMB 0.5 billion (inclusive), and the project construction period is expected to be 21 months. The ADC new product commercial production line construction project is also planned to be implemented in the factory area of CSPC Pharma JS Bio Pharmaceutical Co., Ltd. at No. 519 Cangsheng Road, High-tech Zone, Shijiazhuang. Four production lines and supporting centralized weighing, tail gas absorption systems, and biological wastewater inactivation systems will be built in JS Bio. Process equipment such as reactors, disk centrifuges, chromatography systems, and filling lines will also be purchased. After the project is completed, the production capacity of the original liquid and preparation of JS Bio ADC products will be increased. The total estimated investment of the project is not more than RMB 0.4 billion (inclusive), and the project construction period is expected to be 21 months. This investment is conducive to improving the company's industrialization capabilities in the field of innovative biopharmaceuticals and is highly in line with the company's development strategy of building a leading platform for innovative biopharmaceuticals.
According to the announcement made by CSPC Innovation Pharmaceutical (300765.SZ), its subsidiary, CSPC Pharma, plans to invest in the construction of the "CSPC Pharma JS Bio Large Biopharmaceutical Production Line Construction" and "CSPC Pharma JS Bio ADC New Product Commercial Production Line Construction" projects.
The monoclonal antibody production line project of CSPC Pharma JS Bio is planned to be implemented at No.519 Cangsheng Road, High-tech Zone, Shijiazhuang, the factory area of CSPC Pharma JS Bio Pharmaceutical Co., Ltd. In JS Bio, three production lines and supporting facilities such as material automatic conveying systems and biological wastewater inactivation systems will be built, as well as new facilities such as automatic detection function islands. Process equipment such as disposable bioreactors, disk centrifuges, chromatography systems, lyophilizers, and filling lines will also be purchased. After the project is completed, the production capacity of the original liquid and preparation of JS Bio monoclonal antibody products will be increased. The total estimated investment of the project is not more than RMB 0.5 billion (inclusive), and the project construction period is expected to be 21 months.
The CSPC Pharma JS Bio ADC new product commercial production line construction project is planned to be implemented at No.519 Cangsheng Road, High-tech Zone, Shijiazhuang, the factory area of CSPC Pharma JS Bio Pharmaceutical Co., Ltd. In JS Bio, four production lines and supporting centralized weighing, tail gas absorption systems, and biological wastewater inactivation systems will be built, as well as process equipment such as reactors, disk centrifuges, chromatography systems, and filling lines. After the project is completed, the production capacity of the original liquid and preparation of JS Bio ADC products will be increased. The total estimated investment of the project is not more than RMB 0.4 billion (inclusive), and the project construction period is expected to be 21 months.
This investment is expected to enhance the company's industrialization capabilities in the field of innovative biopharmaceuticals, which is highly consistent with the company's development strategy to build a leading platform for innovative biopharmaceuticals.